glp-1-directed nmda receptor antagonism for obesity treatment Emerging Role of GLP-1 Agonists the of MASH GLP-1 Agonists for Obesity Treatment:

Against this backdrop, researchers explored GLP1 receptor agonistsa class of medicines widely used for diabetes and obesityfor potential neuroprotective and antiinflammatory effects in the brain

Many individuals using GLP-1 medications continue eating many of the same foods as before, although portion sizes often become significantly smaller over time

While they are highly effective for blood sugar control and appetite regulation, many patients experience unexpected digestive side effects

Some highly sensitive individualsoften referred to as fast respondersdo report a dramatic drop in their cravings and a noticeable loss of mental food noise within the first 24 to 48 hours

With less saliva, bacteria can multiply, leading to bad breath, gum disease, or tooth decay over time

These types of positive outcomes dont appear to be atypical